world cancer report - iarc
world cancer report - iarc
world cancer report - iarc
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Fig. 4.42 The FOBT test for colorectal <strong>cancer</strong> (shown here is a Hemoccult II ® test). Three consecutive<br />
stools samples are applied to the test card. After addition of the reaction solution, a blue coloration indicates<br />
the presence of blood. A single positive result among the three samples indicates the need for a<br />
clinical examination of the colon.<br />
per year per life saved), screening for<br />
colorectal <strong>cancer</strong> in the USA has been<br />
evaluated as being below an arbitrary<br />
financial threshold adopted in screening<br />
(US$ 40,000 per year of life gained) and<br />
in this regard compares favourably with<br />
protocols for breast or cervical <strong>cancer</strong><br />
screening. It has been estimated that<br />
screening 200,000 people in Australia<br />
using the FOBT would detect 250<br />
colorectal <strong>cancer</strong>s and prevent as many<br />
as 55 deaths. The FOBT gives the most<br />
cost-effective programme, but prevents<br />
fewer deaths than other programmes. A<br />
single colonoscopy has a greater impact<br />
on <strong>cancer</strong> mortality. Some health authorities<br />
in developed countries acknowledge<br />
the legitimacy of a screening protocol for<br />
colorectal <strong>cancer</strong>. However, the high cost<br />
of a generalized intervention and the limited<br />
acceptance of the tests by the population<br />
explain its limited application. It<br />
has been shown that nurses can perform<br />
sigmoidoscopy as competently as doctors,<br />
as indicated by the duration of the<br />
procedure, the ability to detect neoplasia<br />
and the risk of complications. When a<br />
lesion is detected in these circumstances,<br />
a colonoscopy is performed by a<br />
specialist.<br />
Evidence of outcome<br />
FOBT has been assessed in randomized<br />
trials. An American trial [2] was based on<br />
an annual rehydrated FOBT in volunteers.<br />
The compliance was high (90.2%) and<br />
38% of individuals screened underwent<br />
colonoscopy. There was a 33% reduction<br />
in specific mortality in the screened<br />
group (Table 4.17). Reduction in <strong>cancer</strong><br />
incidence also occurred. In the two<br />
European, population-based, randomized<br />
trials [3,4] conducted in the UK and in<br />
Denmark with a biennial non-rehydrated<br />
FOBT, the compliance was lower (around<br />
60%), only 4% of individuals tested had<br />
colonoscopy and the reduction in mortality<br />
was less (15%).<br />
Screening by sigmoidoscopy has been<br />
evaluated in case-control studies. In the<br />
Kaiser study [13], rigid sigmoidoscopy was<br />
associated with a 59% reduction in mortality<br />
from <strong>cancer</strong> of the rectum and distal<br />
colon. Scandinavian trials have shown less<br />
compliance and a higher yield of detection<br />
with sigmoidoscopy than with the FOBT. A<br />
Screening protocols<br />
Annual faecal occult blood test<br />
Biennial faecal occult blood test<br />
Annual faecal occult blood test<br />
+ fibrosigmoidoscopy every 5 years<br />
Fibrosigmoidoscopy every 5 years<br />
Colonoscopy every 10 years<br />
Colonoscopy once in a lifetime<br />
Table 4.16 Options for population-based screening<br />
protocols for colorectal <strong>cancer</strong> (in males and<br />
females, from the age of 50 years).<br />
cohort study in the USA has shown that<br />
screening by endoscopy reduces mortality<br />
from colorectal <strong>cancer</strong> by 50% and incidence<br />
by 40% [8]. Primary endoscopic<br />
screening is increasingly favoured as compared<br />
to the FOBT protocol [9].<br />
There is indirect evidence that primary<br />
colonoscopy may reduce <strong>cancer</strong> mortality.<br />
The National Polyp Study in the USA has<br />
shown a 75% reduction in the risk of<br />
colorectal <strong>cancer</strong> after polypectomy<br />
[10,11]. Among persons of average risk,<br />
above age 50, screening by colonoscopy<br />
reveals <strong>cancer</strong> in 0-2.2% and large adenomas<br />
in 3-11%. The number of colonoscopies<br />
needed to detect one <strong>cancer</strong> in<br />
screening is estimated at 143 for individuals<br />
of either sex, aged at least 50, and 64<br />
for males aged at least 60 years. The number<br />
of colonoscopies needed to detect one<br />
<strong>cancer</strong> in patients with a positive FOBT is<br />
Screened annually Unscreened<br />
Number of people 15,550 15,394<br />
Number of colorectal <strong>cancer</strong>s detected 323 356<br />
Number of deaths from colorectal <strong>cancer</strong> 82 121<br />
Mortality ratio 0.67 1.00<br />
(deaths in screened/deaths in unscreened)<br />
Table 4.17 The efficacy of screening by FOBT as reflected by the reduced mortality due to colorectal<br />
<strong>cancer</strong>s diagnosed in the group subject to annual screening in comparison with the unscreened group.<br />
Screening for colorectal <strong>cancer</strong><br />
165